Table 1.
Gross total resection rate using intraoperative navigation with 5-aminolevulinic acid.
| No. | Study | n | His-Pat | Dose | Supply | GTR (%) | PFS-6 (%) | PFS (Months) | OS (Months) |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Stummer, et al. (2000) [16] | 52 | GBM | 20 mg/kg | 3 h before induction of anesthesia | 63.5 [33/52] | 20 | ||
| 2. | Stummer, et al. (2006) [27] | 139 | HGG | 20 mg/kg | 2–4 h before induction of anesthesia | ||||
| Study group | 139 | WHO IV—135 WHO III—4 |
65 [90/139] | 41.0 | >55 y–14.1 <55y–18 |
||||
| Control group | 131 | WHO IV—125 WHO III—5 |
36 [57/131] | 21.1 | >55 y–11.4 <55 y–17.5 |
||||
| 3. | Nabavi, et al. (2009) [46] | 36 | HGG (recurrent) WHO IV—21 WHO III—13 Progression of LGG—2 |
20 mg/kg | 3 h before induction of anesthesia | 19.4% [7/36] | 7.4 9.9 |
||
| 4. | Feigl, et al. (2010) [43] | 18 | HGG WHO IV—15 Primary—14 Recurrent—1 WHO III—3 |
20 mg/kg | 6 h before surgery | 88.9 | |||
| 5. | Diez Valle, et al. (2010) [32] | 36 | GBM | 20 mg/kg | 2–4 before induction of anesthesia | 83.3 [30/36] >98–100% |
|||
| 28 | Primary | 82% [23/28] | 6.5 | 15.7 | |||||
| 8 | Recurrent | 87.5% [7/8] | 5.3 | 7.9 | |||||
| 6. | Tsugu, et al. (2011) [42] | 11 | HGG WHO IV—9 WHO III—2 |
1000 mg | 2–4 before induction of anesthesia | 54.5 [6/11] | |||
| 7. | Idoate, et al. (2011) [36] | 30 | GBM Recurrent—9 |
20 mg/kg | 2–4 h before surgery | 83.3 [25/30] >98–100% |
|||
| 8. | Schucht, et al. (2012) [37] | 53 | GBM | 20 mg/kg | 2–4 h before induction of anesthesia | 96.2 [51/53] n.r.e. >0.175–96.2 cm3 [51/53] n.r.e.: 89% [47/53] >98–96%—51/53 >90–98%—52/53 |
|||
| 9. | Tejada-Solis, et al. (2012) [35] | 65 | GBM | 20 mg/kg | 2 h before induction of anesthesia | 78.5 [51/65] | 16 | ||
| 10. | Eyupoglu, et al. (2012) [40] | 37 | HGG | 20 mg/kg | 3 h before induction of anesthesia | 56.8 [21/37] | |||
| WHO IV—30 | 63.3 [19/30] | ||||||||
| WHO III—7 | 28.6 [2/7] | ||||||||
| 11. | Cortnum, et al. (2012) [41] | 13 | HGG–WHO IV | 1500 mg | 2–4 h before surgery | 70 [7/10] 54 [7/13] |
|||
| 12 | GBM | Total—7/12 Near total—4/12 |
|||||||
| 1 | Other—PNET–WHO IV | Near total—1/1 | |||||||
| 12. | Roessler, et al. (2012) [39] | 10 | GBM | 20 mg/kg | no data | 50 [5/10] | |||
| 13. | Pastor, et al. (2013) [44] | 30 | HGG | 20 mg/kg | 2–4 h before induction of anesthesia | 66.7 [24/36] >98%—66.7 [24/36] >95%—5.6 [2/36] >90%—19.4 [7/36] |
|||
| 14. | Diez Valle, et al. (2014) [31] | 251 | HGG | no data | no data | 69.1 | |||
| Study group | 131 | 90.1 [118/131] | 71.2 | ||||||
| WHO IV—122 | 69.1 | ||||||||
| WHO III—9 | |||||||||
| Control group | 120 | 66.7 [80/120] | 52.5 | ||||||
| WHO IV—102 | 48.1 | ||||||||
| WHO III—18 | |||||||||
| 15. | Della Pupa, et al. (2014) [33] | 94 | HGG | 20 mg/kg | 2–4 h before surgery | 92.6 >98%—93 [88/94] >90%—100 [94/94] |
|||
| Primary—61 Recurrent—33 |
93 [57/61] 79 [31/33]] |
||||||||
| WHO IV—81 WHO III—13 |
96 [78/81] 79 [10/13] |
||||||||
| 16. | Piquer, et al. (2014) [38] | 30 | HGG WHO IV—23 WHO III—4 MET—3 |
20 mg/kg | 6 h before surgery | 74.1 [20/27] 78.2 [18/23] 50 [2/4] 100 [3/3] |
|||
| 17. | Della Pupa, et al. (2017) [34] | 79 | GBM | 20 mg/kg | 2–4 h before surgery | 77.2 | 11 | 21 | |
| 18. | Ming Chan, et al. (2018) [45] | 16 | HGG WHO IV—10 WHO III—2 LGG—3 Other—1 |
20 mg/kg | 3–4 before induction of anesthesia | 68.8 [11/16] Total—56.3 [9/16] >95%—12.5 [2/16] >90%—31.25 [5/16] |
GBM: glioblastoma multiforme, HGG: high-grade glioma, LGG: low-grade glioma, MET: metastases, GTR: gross total resection, OS: overall survival rate, PFS: progression-free survival, PFS-6: 6 months progression-free survival, n.r.e.: no residual enhancement, >98%: resection of more than 98% of the tumor volume, >95%: resection of more than 95% of the tumor volume, >90%: resection of more than 90% of the tumor volume.